title: Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy.
abstract: BACKGROUND
  The study's objective was to assess the predictive factors of anemia induced by chemotherapy in early breast cancer patients.
  
  
  METHODS
  Patients treated by adjuvant or neo-adjuvant anthracyclin-based regimens with or without taxanes between 1998 and 2006 in a French university hospital were studied. Chemotherapy included. Anemia was defined as a hemoglobin (Hb) concentration lower than 12 g/dL. Multivariate analysis by logistic regression was used to search for baseline risk factors linked to the occurrence of anemia.
  
  
  RESULTS
  Among 378 patients, anemia was observed in 64% of cases. The occurrence of anemia was significantly related to 6 risk factors: exposure to taxanes (HR 11.5, 95% CI, 2.5-52.6), high dose of anthracyclin (epirubicin 100 mg/m²)(HR 4.3; 95% CI, 2.8-8), Hb at baseline < 13.5 g/d (HR 4.3; 95% CI, 2.6-7.1), mastectomy (HR 2.5; 95% CI, 1.4-3.3), age >60 (HR 2.5; 95% CI, 1.4-5) years old (HR 2.5; 95% CI, 1.4-5) and Body Mass Index (BMI) ≤ 25 kg/m² (HR 1.7; 95% CI, 1.0-2.8).
  
  
  CONCLUSIONS
  Taking into account the following factors: type of chemotherapy, BMI, age, Hb at baseline should allow a better identification of patients at risk of anemia.
authors: Pharmacy Department, Centre Régional de Lutte Contre Cancer Léon Bérard, Lyon, France.
authors: N
authors: N
authors: Chaumard
authors: S
authors: S
authors: Limat
authors: C
authors: C
authors: Villanueva
authors: V
authors: V
authors: Nerich
authors: P
authors: P
authors: Fagnoni
authors: F
authors: F
authors: Bazan
authors: L
authors: L
authors: Chaigneau
authors: E
authors: E
authors: Dobi
authors: L
authors: L
authors: Cals
authors: X
authors: X
authors: Pivot
mesh_terms: D000328:Adult; D000367:Age Factors; D000740:Anemia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D000077143:Docetaxel; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008408:Mastectomy; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D006454:Hemoglobins; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide